AroCell 将来の成長

Future 基準チェック /26

AroCellは、25.6%と25.9%でそれぞれ年率25.6%で利益と収益が成長すると予測される一方、EPSはgrowで5.4%年率。

主要情報

25.6%

収益成長率

5.4%

EPS成長率

Life Sciences 収益成長	43.8%
収益成長率	25.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	26 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

OM:AROC - アナリストの将来予測と過去の財務データ ( )SEK Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	94	N/A	N/A	N/A	1
12/31/2025	74	-35	2	6	1
12/31/2024	58	-42	-5	N/A	1
9/30/2024	52	-51	-8	-7	N/A
6/30/2024	48	-54	-9	-8	N/A
3/31/2024	45	-56	-14	-13	N/A
12/31/2023	43	-59	-15	-13	N/A
9/30/2023	46	-59	-19	-15	N/A
6/30/2023	46	-57	-15	-11	N/A
3/31/2023	40	-57	-14	-10	N/A
12/31/2022	37	-59	-18	-14	N/A
9/30/2022	30	-62	-21	-21	N/A
6/30/2022	26	-69	-27	-26	N/A
3/31/2022	20	-59	-30	-30	N/A
12/31/2021	12	-50	-29	-28	N/A
9/30/2021	6	-36	-23	-23	N/A
6/30/2021	0	-25	-21	-21	N/A
3/31/2021	0	-25	-20	-20	N/A
12/31/2020	0	-24	-19	-19	N/A
9/30/2020	0	-24	-19	-19	N/A
6/30/2020	0	-22	-16	-16	N/A
3/31/2020	0	-21	-16	-16	N/A
12/31/2019	0	-21	-15	-15	N/A
9/30/2019	0	-20	-16	-16	N/A
6/30/2019	0	-21	-18	-18	N/A
3/31/2019	1	-22	-18	-18	N/A
12/31/2018	1	-21	-16	-16	N/A
9/30/2018	1	-21	-15	-15	N/A
6/30/2018	1	-19	N/A	-14	N/A
3/31/2018	0	-17	N/A	-13	N/A
12/31/2017	1	-17	N/A	-15	N/A
9/30/2017	0	-13	N/A	-16	N/A
6/30/2017	0	-12	N/A	-13	N/A
3/31/2017	0	-11	N/A	-11	N/A
12/31/2016	0	-9	N/A	-7	N/A
9/30/2016	1	-9	N/A	-8	N/A
6/30/2016	0	-8	N/A	-8	N/A
3/31/2016	0	-8	N/A	-7	N/A
12/31/2015	0	-7	N/A	-9	N/A
9/30/2015	N/A	-9	N/A	N/A	N/A
6/30/2015	N/A	-8	N/A	N/A	N/A
3/31/2015	N/A	-8	N/A	N/A	N/A
12/31/2014	N/A	-6	N/A	N/A	N/A
9/30/2014	N/A	-5	N/A	N/A	N/A
6/30/2014	N/A	-5	N/A	N/A	N/A
3/31/2014	N/A	-4	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AROC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AROC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: AROC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: AROCの収益 ( 25.9% ) Swedish市場 ( -0.04% ) よりも速いペースで成長すると予測されています。

高い収益成長: AROCの収益 ( 25.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AROCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

AroCell 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates fall by 12%

Price target decreased to kr2.30

Consensus revenue estimates increase by 17%

Price target decreased to kr2.00

Recent updates

New major risk - Market cap size

AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate Cancer

Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)

AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

AroCell AB (publ), Annual General Meeting, May 22, 2024

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Consensus revenue estimates fall by 12%

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

Price target decreased to kr2.30

High number of new and inexperienced directors

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

Price target decreased to kr2.00

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

Head of Operations recently bought kr81k worth of stock

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

New 90-day high: kr3.41

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

Head of Operations recently bought kr91k worth of stock

Head of Operations recently bought kr91k worth of stock

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

New 90-day low: kr2.43

Earnings released

New 90-day high - kr3.64

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘